Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)

NCT07025005 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Peripheral Neuropathy
Multiple Myeloma, Neoplasms

Interventions

DRUG: Bortezomib + Lenalidomide + Dexamethasone + Fenofibrate 160 mg tablet
DRUG: Bortezomib + Lenalidomide + Dexamethasone

Sponsor

Tanta University